Overview

UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia

Status:
NOT_YET_RECRUITING

Trial end date:
2031-12-31

Target enrollment:

Participant gender:

Summary

This Phase II open-label interventional clinical trial aims to evaluate the efficacy of romiplostim, in patients with severe aplastic anemia (SAA), both treatment nave and relapsed/refractory, in inducing trilineage hematopoiesis in children and young adults.

Phase:

PHASE2

Details

Lead Sponsor:

Anjali Sharathkumar

Collaborators:

Department of Health and Human Services
Food and Drug Administration (FDA)

Treatments:

Immunosuppression Therapy
romiplostim